Prostate Cancer Trials

RTOG 0924

RTOG 0924 - Androgen deprivation therapy and high does radiotherapy with or without pelvic radiotherapy in unfavorable intermediate or favorable high-risk prostate cancer.

1. What type of cancer? What stage?
   1. Prostate cancer, unfavorable intermediate or favorable high-risk.
2. Who is eligible?
   1. Men who will be treated with definitive radiation.
3. How will I be treated?
   1. This trial looks at two methods for treating someone with radiation.

EA8153 (CHAARTED2)

EA8153 (CHAARTED2) - Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial.

1. What type of cancer? What state?
   1. Prostate cancer.
2. Who is eligible?
   1. Men who have previously received chemotherapy.
3. How will I be treated?
   1. This trial looks at adding a drug known as Cabazitaxel to Abiraterone.

NRG GU 005

NRG GU 005 - Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

1. What type of cancer? What stage?
   1. Prostate cancer, localized intermediate risk.
2. Who is eligible?
   1. Men who will be treated with definitive radiation.
3. How will I be treated?
   1. This trial looks at two methods of accelerated radiation therapy.

NRG GU 006

NRG GU-006 - A Phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with Apalutamide in recurrent prostate cancer.

1. What type of cancer? What stage?
   1. Prostate cancer that has recurred after surgery.
2. Who is eligible?
   1. Men who will be treated with salvage radiation therapy.
3. How will I be treated?
   1. This trial looks at adding in apalutamide, an anti-androgen that is approved in the treatment of prostate cancer.

NRG GU 002

NRG GU-002 - Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant docetaxel.

1. What type of cancer? What stage?
   1. Prostate cancer.
2. Who is eligible?
   1. Men who have received a prostatectomy.
3. How will I be treated?
   1. This trial looks at adding in apalutamide, an anti-androgen that is approved in the treatment of prostate cancer.

S1802

S1802 - Phase III randomized trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer

1. What type of cancer? What stage?
   1. Prostate cancer with limited metastases.
2. Who is eligible?
   1. Men who are going to be treated with systemic therapy (hormone therapy or chemotherapy).
3. How will I be treated?
   1. The trial looks at adding in definitive local treatment (either surgery or radiation).

For physicians: more information about this specific trial at clinicaltrials.gov.